Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Ligand Pharmaceuticals's EV/EBITDA was 38.2× on Nov 11, 2026, against 63.8× a year earlier. Over the last 5 years it ranged from 7.8× to 164.6×, with a median of 24.3×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 38.2× | −20.3 |
| 2025 | Dec 31, 2025 | 58.5× | −34.7 |
| 2024 | Dec 31, 2024 | 93.3× | +62.2 |
| 2023 | Dec 29, 2023 | 31.0× | +22.2 |
| 2022 | Dec 30, 2022 | 8.8× | −7.3 |
| 2021 | Dec 31, 2021 | 16.1× | −17.7 |
| 2020 | Dec 31, 2020 | 33.8× | +23.1 |
| 2019 | Apr 30, 2019 | 10.7× | +0.3 |
| 2018 | Dec 31, 2018 | 10.4× | −28.1 |
| 2017 | Dec 29, 2017 | 38.6× | −6.3 |
| 2016 | Dec 30, 2016 | 44.9× | −24.2 |
| 2015 | Dec 31, 2015 | 69.1× | +22.9 |
| 2014 | Dec 31, 2014 | 46.3× | −26.4 |
| 2013 | Dec 31, 2013 | 72.6× | −95.7 |
| 2012 | Dec 31, 2012 | 168.3× | – |
See a number that looks wrong?